Unverified50% confidenceDecision RuleExact time
When deploying biomedical large models, it is recommended to test the change in the model's abstention rate before and after fine-tuning using a benchmark similar to MedAbstain, in order to avoid erosion of the safety guardrails.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
11/9/2026
First Seen
Valid until: 2/7/2027
Sources
Related Entities
Related Claims
UnverifiedThe original paper studied how performance degrades when only approximate posterior information is available or when measurements are affected by noise, and proposed several strategies for introducing design constraints driven by biomedical applications.69% similarUnverifiedAlphaFold lowered the barrier to early target assessment and structure-based drug design, but it provides structural hypotheses rather than biological validation; predicted structures still require experimental confirmation and cannot replace functional experiments and preclinical toxicology assessments.67% similarUnverifiedA reasonable approach is to determine the optimal oversampling level through small-scale experiments for the target disease and model architecture, while monitoring disease-level performance changes.67% similarUnverifiedHealth benchmarks usually refer to evaluating a model's level of medical knowledge using standardized medical question-answering datasets (such as MedQA, PubMedQA, etc.), with accuracy as the main metric; such tests assume by default that the model should try to give an answer, but Tabibu's safety layer actively refuses diagnosis and so on, causing many questions it could have answered correctly to be intercepted by safety fallbacks.67% similarUnverifiedBioPhys-Bridge emphasizes the evaluation of capabilities including attribution, faithfulness, hallucination suppression, and biological experiment design.67% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1149940API
curl https://kongchang.com/api/v1/knowledge/claims/1149940MCP
get_claim(id=1149940)